Credit Suisse Ag Jounce Therapeutics, Inc. Transaction History

Credit Suisse Ag

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.64 - $1.99 $150 - $467	-235 Reduced 99.16%	2 $0
Q3 2022 Nov 10, 2022	BUY	$2.73 - $4.92 $540 - $974	198 Added 507.69%	237 $1,000
Q2 2022 Aug 12, 2022	BUY	$2.8 - $7.67 $109 - $299	39 New	39 $0
Q4 2021 Feb 14, 2022	SELL	$7.11 - $9.64 $1.18 Million - $1.6 Million	-165,863 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$5.04 - $8.73 $1.94 Million - $3.36 Million	-384,699 Reduced 69.87%	165,863 $1.23 Million
Q2 2021 Aug 16, 2021	BUY	$6.58 - $10.66 $302,541 - $490,136	45,979 Added 9.11%	550,562 $3.74 Million
Q1 2021 May 14, 2021	BUY	$6.73 - $13.87 $3.4 Million - $7 Million	504,583 New	504,583 $5.18 Million
Q3 2018 Nov 13, 2018	SELL	$6.5 - $8.37 $77,135 - $99,326	-11,867 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$7.27 - $21.88 $17,811 - $53,606	-2,450 Reduced 17.11%	11,867 $91,000
Q1 2018 May 15, 2018	BUY	$13.4 - $28.4 $191,847 - $406,602	14,317 New	14,317 $321,000
Q4 2017 Feb 14, 2018	SELL	$12.52 - $17.82 $133,413 - $189,889	-10,656 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$11.17 - $16.99 $119,027 - $181,045	10,656	10,656 $166,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.